Pegfilgrastim in Supportive Care of Hodgkin Lymphoma

Abstract

Neutropenia and febrile neutropenia are common and potentially life-threating events associated with chemotherapy treatment in Hodgkin lymphoma (HL). Neutropenia-related infectious events could be an issue both for direct clinical consequences and for delay in treatment delivery, affecting final outcomes in a potentially highly curable disease. Pegfilgrastim is the pegylated form of filgrastim, the recombinant form of human G-CSF, capable of prevent and mitigate neutropenic effects of chemotherapy, when adopted as primary prophylaxis in several hematological malignancies. No updated version of major international guidelines provides clear indication on prophylaxis use of pegfilgrastim in HL to prevent febrile neutropenia episodes in HL. Moreover, to date, scarce and non-uniform clinical experiences evaluating pegfilgrastim as prophylaxis in HL are present in the literature. Herein, we propose a brief summary of the literature data about efficacy and safety of the use of pegfilgrastim as primary prophylaxis in HL during chemotherapy treatment.

Hodgkin Lymphoma—The Spectrum from Diagnostics to Molecular Science, Movement and Current Treatment Approaches

“…Finally, the commentary on the use of Pegfilgrastim in HL by Cerchione et [8] highlights not only the importance of lymphoma-specific treatment, but also the management of side effects, since therapy-induced neutropenia can be a life-threatening event in HL patients.…”